Principal Investigator Bernhardt Trout
Biopharmaceuticals are complex, metastable protein/antibody molecules. Ideally, they should be delivered to patients in as high a concentration as possible in aqueous solution. From the moment that they are placed in solution, however, they degrade, the most problematic routes of degradation being aggregation, oxidation, and deamidation. We have worked in all three areas, elucidating mechanisms, developing predictive strategies, and inventing a completely new approach to prevent aggregation.